The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised controlled trial

Table 1 Eligibility criteria

Inclusion criteria	Exclusion criteria
● Aged ≥18 years	● Contraindications to: P-PCI, CMRI, gadolinium-based and/or iodinated contrast agents, or study medications: Adenosine, SNP, Aspirin, Thienopyridine and Bivalirudin
● Informed ASSENT (verbal consent) prior to angiography
● STEMI ≤6 h of symptom onset, requiring P-PCI
● STEMI ≤6 h of symptom onset, requiring P-PCI	● SBP ≤90 mmHg
● Single-vessel coronary artery disease (non-culprit disease <70% stenosis at angiography)	● Cardiogenic shock
	● Previous Q wave myocardial infarction
	● Culprit lesion not identified or located in a bypass graft
● TIMI flow 0/1 at angiography
● TIMI flow 0/1 at angiography	● Stent thrombosis
● QTc <450 ms	● Left main disease
	● Known severe asthma
	● Known stage 4 or 5 chronic kidney disease (eGFR <30 mL/min/1.73 m²)
	● Pregnancy

CMRI, cardiac magnetic resonance imaging; e-GFR, estimated glomerular filtration rate; P-PCI, primary percutaneous coronary intervention; SBP, systolic blood pressure; TIMI, Thrombolysis in Myocardial Infarction.

ISSN: 1745-6215